Tuebingen

• This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) Ended
  2024-511503-41-00 3 2021-08-13 Advanced or metastatic solid tumors
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib … Ended
  2022-503107-21-00 3 2021-05-14 NRAS-mutant advanced cutaneous melanoma
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial (A … Ended
  2024-518182-10-00 5 2021-01-13 Acoustic schwannoma
• A Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients wit … Ended
  2024-517785-42-00 5 2020-10-08 Renal cell carcinoma (RCC)
• This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPE Ended
  2024-512086-14-00 5 2020-09-23 Biliary Atresia
• Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with brain tumors Ended
  2024-517575-20-00 4 2020-08-24 different types of brain tumors
• A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended
  2023-507389-15-00 4 2020-02-26 Advanced Melanoma
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma wi … Ended
  2024-514479-16-00 4 2019-10-28 Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with
• A Single-arm Study of Intrathecal SHP611 in Subjects with Metachromatic Leukodystrophy Ended
  2024-514402-31-00 4 2019-09-09 Late Metachromatic Leukodystrophy (MLD)
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• A research study in children with low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day Ended
  2023-506829-11-00 5 2019-05-29 Growth Hormone Deficiency in children
• A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended
  2023-505476-29-00 5 2019-04-05 Giant Cell Arteritis
• "Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients … Ended
  2023-510020-68-00 7 2019-03-18 Hepatitis B, Chronic
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patien … Ended
  2023-508424-34-00 5 2019-02-11 Moderate to Severe Plaque Type Psoriasis
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors

Showing 553–576 of 600 trials